Ligand Pharmaceuticals/ US53220K5048 /
| 2025-01-14 9:59:55 PM | Chg. +2.61 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 108.29USD | +2.46% | 3,182 Turnover: 339,931.82 |
-Bid Size: - | -Ask Size: - | 2.05 bill.USD | - | 35.94 |
Assets
| 2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | .3720 | 1.8190 | 4.2120 | 5.3720 | 7.1850 | ||||||
| Intangible Assets | 48.3470 | 204.7050 | 228.5840 | 219.7930 | 210.4480 | ||||||
| Long-Term Investments | 29.7280 | 8.3450 | 6.4380 | 0.0000 | - | ||||||
| Fixed Assets | 318.3570 | 438.5320 | 434 | 390.2630 | 371.2700 | ||||||
| Inventories | 1.6330 | 1.9230 | 4.3730 | 7.1240 | 7.2960 | ||||||
| Accounts Receivable | .7310 | 14.7000 | 25.5960 | 55.8500 | 30.3870 | ||||||
| Cash and Cash Equivalents | 97.4280 | 18.7520 | 20.6200 | 117.1640 | 71.5430 | ||||||
| Current Assets | 215.5720 | 163.0530 | 237.0210 | 870.5400 | 1,123.6450 | ||||||
| Total Assets | 533.9290 | 601.5850 | 671.0210 | 1,260.8030 | 1,494.9150 | ||||||
Liabilities
| 2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.0830 | 2.7340 | 2.2590 | 4.1830 | 2.4200 | ||||||
| Long-term debt | 205.3720 | 0.0000 | 0.0000 | 609.8640 | 638.9590 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 229.5380 | 260.2950 | 271.2330 | 699.8890 | 727.6830 | ||||||
| Share Capital | .0200 | .0210 | .0210 | .0210 | .0170 | ||||||
| Total Equity | 304.3910 | 341.2900 | 399.7880 | 560.9140 | 767.2320 | ||||||
| Minority Interests | 0.0000 | 0.0000 | 0.0000 | - | - | ||||||
| Total liabilities equity | 533.9290 | 601.5850 | 671.0210 | 1,260.8030 | 1,494.9150 | ||||||
Income Statement
| 2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 71.9140 | 108.9730 | 141.1020 | 251.4530 | 120.2820 | ||||||
| Depreciation (total) | 2.6270 | - | - | - | - | ||||||
| Operating Result | 27.3290 | 43.8850 | 68.0760 | 163.7270 | 807.0760 | ||||||
| Interest Income | -11.8020 | -12.1780 | -11.4000 | -48.2760 | -7.3150 | ||||||
| Income Before Taxes | 35.3290 | 7.9600 | 57.2310 | 173.3300 | 796.6390 | ||||||
| Income Taxes | 219.5960 | -10.3270 | -44.6750 | -30.0090 | -167.3370 | ||||||
| Minority Interests Profit | -2.3800 | 0.0000 | 0.0000 | - | - | ||||||
| Net Income | 257.3050 | -1.6360 | 12.5560 | 143.3210 | 629.3020 | ||||||
Per Share
Cash Flow
| 2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 41.7270 | 63.0010 | 93.5680 | 194.0590 | -29.3360 | ||||||
| Cash Flow from Investing Activities | -112.8620 | -143.1920 | -84.1770 | -423.2690 | 466.9180 | ||||||
| Cash Flow from Financing | 8.3600 | 1.5150 | -7.5230 | 328.5850 | -485.1720 | ||||||
| Decrease / Increase in Cash | -62.7750 | -78.6760 | 1.8680 | 99.3750 | -47.5900 | ||||||
| Employees | - | - | - | - | - | ||||||
